Clinical efficacy of ZelanteDVT™ catheter rheolytic thrombectomy in the single-session treatment of patients with subacute deep venous thrombosis.

Abstract

To evaluate the clinical efficacy and safety of novel ZelanteDVT™ catheter rheolytic thrombectomy in the single-session endovascular management of subacute deep venous thrombosis (DVT). A retrospective study was performed on 31 patients with subacute DVT who underwent ZelanteDVT™ catheter rheolytic thrombectomy. Procedure data, associated complications, and venous patency score were recorded. The deep venous patency and post-thrombotic syndrome (PTS) rate were assessed in all patients during follow-up visits. After procedure, 19.4% (6/31) patients improved to grade III thrombus removal, while the remaining patients improved to grade II. Significant iliac vein compression syndrome was identified in 54.8% (17/31) patients, and 82.4% (14/17) of them received stent implantation. No serious procedure-related complications occurred. The median follow-up time was 13months. The primary patency rate at 12months was 83.87%, and the incidence of PTS was 19.35%. This novel rheological thrombectomy catheter seems to have a promising application prospect for single-session treatment of subacute DVT.